Literature DB >> 34785522

Employment disruption among women with gynecologic cancers.

Roni Nitecki1, Shuangshuang Fu2, Kirsten A Jorgensen3, Lauren Gray4, Carolyn Lefkowits5, Benjamin D Smith6, Larissa A Meyer3, Alexander Melamed7, Sharon H Giordano2, Pedro T Ramirez3, Jose Alejandro Rauh-Hain1.   

Abstract

BACKGROUND: Adverse employment outcomes pose significant challenges for cancer patients, though data patients with gynecologic cancers are sparse. We evaluated the decrease in employment among patients in the year following the diagnosis of a gynecologic cancer compared with population-based controls.
METHODS: Patients aged 18 to 63 years old, who were diagnosed with cervical, ovarian, endometrial, or vulvar cancer between January 2009 and December 2017, were identified in Truven MarketScan, an insurance claims database of commercially insured patients in the USA. Patients working full- or part-time at diagnosis were matched to population-based controls in a 1:4 ratio via propensity score. Multivariable Cox proportional hazards models were used to evaluate the risk of employment disruption in patients versus controls.
RESULTS: We identified 7446 women with gynecologic cancers (191 vulvar, 941 cervical, 1839 ovarian, and 4475 endometrial). Although most continued working following diagnosis, 1579 (21.2%) changed from full- or part-time employment to long-term disability, retirement, or work cessation. In an adjusted model, older age, the presence of comorbidities, and treatment with surgery plus adjuvant therapy versus surgery alone were associated with an increased risk of employment disruption (p<0.0003, p=0.01, and p<0.0001, respectively) among patients with gynecologic cancer. In the propensity-matched cohort, patients with gynecologic cancers had over a threefold increased risk of employment disruption relative to controls (HR 3.67, 95% CI 3.44 to 3.95).
CONCLUSION: Approximately 21% of patients with gynecologic cancer experienced a decrease in employment in the year after diagnosis. These patients had over a threefold increased risk of employment disruption compared with controls. © IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cervical cancer; ovarian cancer; quality of life (PRO)/palliative care; uterine cancer; vulvar and vaginal cancer

Mesh:

Year:  2021        PMID: 34785522      PMCID: PMC9035315          DOI: 10.1136/ijgc-2021-002949

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   4.661


  34 in total

1.  Temporal patterns of conditions and symptoms potentially associated with ovarian cancer.

Authors:  Michelle L Wynn; Stella Chang; Lucy A Peipins
Journal:  J Womens Health (Larchmt)       Date:  2007-09       Impact factor: 2.681

2.  Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas.

Authors:  David R Lairson; Shuangshuang Fu; Wenyaw Chan; Li Xu; Zeena Shelal; Lois Ramondetta
Journal:  Gynecol Oncol       Date:  2017-02-10       Impact factor: 5.482

3.  The sensitivity of Medicare claims data for case ascertainment of six common cancers.

Authors:  G S Cooper; Z Yuan; K C Stange; L K Dennis; S B Amini; A A Rimm
Journal:  Med Care       Date:  1999-05       Impact factor: 2.983

4.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

5.  Development of a comorbidity index using physician claims data.

Authors:  C N Klabunde; A L Potosky; J M Legler; J L Warren
Journal:  J Clin Epidemiol       Date:  2000-12       Impact factor: 6.437

6.  COVID-19's impact on the U.S. labor market as of September 2020.

Authors:  Erica L Groshen
Journal:  Bus Econ       Date:  2020-11-13

7.  When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer.

Authors:  Vanessa L Beesley; Kate Webber; Christina M Nagle; Anna DeFazio; Andreas Obermair; Merran Williams; Michael Friedlander; Penelope M Webb
Journal:  Gynecol Oncol       Date:  2020-08-06       Impact factor: 5.482

8.  Results from a prospective longitudinal survey of employment and work outcomes in newly diagnosed cancer patients during and after curative-intent chemotherapy: A Wisconsin Oncology Network study.

Authors:  Amye J Tevaarwerk; Kris Kwekkeboom; Kevin A Buhr; Alexandra Dennee; William Conkright; Adedayo A Onitilo; Emily Robinson; Harish Ahuja; Roger W Kwong; Ranveer Nanad; Douglas A Wiegmann; Karen Chen; Noelle K LoConte; Kari B Wisinski; Mary E Sesto
Journal:  Cancer       Date:  2020-11-24       Impact factor: 6.860

9.  Return to work after cancer treatment of gynecologic cancer in Japan.

Authors:  Keiichiro Nakamura; Hisashi Masuyama; Takeshi Nishida; Junko Haraga; Naoyuki Ida; Masayuki Saijo; Tomoko Haruma; Tomoyuki Kusumoto; Noriko Seki; Yuji Hiramatsu
Journal:  BMC Cancer       Date:  2016-07-29       Impact factor: 4.430

10.  Medical costs and productivity losses of cancer survivors--United States, 2008-2011.

Authors:  Donatus U Ekwueme; K Robin Yabroff; Gery P Guy; Matthew P Banegas; Janet S de Moor; Chunyu Li; Xuesong Han; Zhiyuan Zheng; Anita Soni; Amy Davidoff; Ruth Rechis; Katherine S Virgo
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-06-13       Impact factor: 17.586

View more
  1 in total

1.  Climacteric symptoms in postoperative patients among endometrial cancer, cervical cancer, and ovarian cancer: a cross-sectional study.

Authors:  Yuko Horiba; Tetsuhiro Yoshino; Megumi Yokota; Takashi Iwata; Kenji Watanabe; Masaru Mimura; Daisuke Aoki
Journal:  Support Care Cancer       Date:  2022-05-08       Impact factor: 3.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.